{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:59:43Z","timestamp":1789822783648,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,7,3]],"date-time":"2015-07-03T00:00:00Z","timestamp":1435881600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s00198-015-3216-9","type":"journal-article","created":{"date-parts":[[2015,7,2]],"date-time":"2015-07-02T08:23:45Z","timestamp":1435825425000},"page":"81-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2313-7387","authenticated-orcid":false,"given":"G. A.","family":"Otaify","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"Aglan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Elnashar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A. S.","family":"El Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Temtamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,3]]},"reference":[{"key":"3216_CR1","doi-asserted-by":"crossref","first-page":"540178","DOI":"10.4061\/2011\/540178","volume":"2011","author":"IM Ben Amor","year":"2011","unstructured":"Ben Amor IM, Glorieux FH, Rauch F (2011) Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta. J Osteoporos 2011:540178","journal-title":"J Osteoporos"},{"key":"3216_CR2","first-page":"183","volume":"12","author":"O Semler","year":"2012","unstructured":"Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P, Schoenau E (2012) First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 12:183\u2013188","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"3216_CR3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ajhg.2010.02.022","volume":"86","author":"Y Alanay","year":"2010","unstructured":"Alanay Y, Avaygan H, Camacho N, Utine G, Boduroglu K, Aktas D, Alikasifoglu M, Tuncbilek E, Orhan D, Bakar FT, Zabel B, Superti-Furga A, Bruckner-Tuderman L, Curry CJ, Pyott S, Byers PH, Eyre DR, Baldridge D, Lee B, Merrill AE, Davis EC, Cohn DH, Akarsu N, Krakow D (2010) Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 86:551\u2013559","journal-title":"Am J Hum Genet"},{"key":"3216_CR4","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ajhg.2011.01.015","volume":"88","author":"J Becker","year":"2011","unstructured":"Becker J, Semler O, Gilissen C, Li Y, Bolz HJ, Giunta C, Bergmann C, Rohrbach M, Koerber F, Zimmermann K, de Vries P, Wirth B, Schoenau E, Wollnik B, Veltman J, Hoischen A, Netzer C (2011) Exome sequencing identifies truncating mutations in human SERPINF1in autosomal recessive osteogenesis imperfecta. Am J Hum Genet 88:362\u2013371","journal-title":"Am J Hum Genet"},{"key":"3216_CR5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/ng1968","volume":"39","author":"WA Cabral","year":"2007","unstructured":"Cabral WA, Chang W, Barnes AM, Weis M, Scott MA, Leikin S, Makareeva E, Kuznetsova NV, Rosenbaum KN, Tifft CJ, Bulas DI, Kozma C, Smith PA, Eyre DR, Marini JC (2007) Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal\/severe osteogenesis imperfecta. Nat Genet 39:359\u2013365 (Erratum: Nat Genet. (2008)40: 927)","journal-title":"Nat Genet"},{"key":"3216_CR6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ajhg.2009.09.001","volume":"85","author":"FS Dijk Van","year":"2009","unstructured":"Van Dijk FS, Nesbitt IM, Zwikstra EH, Nikkels PGJ, Piersma SR, Fratantoni SA, Jimenez CR, Huizer M, Morsman AC, Cobben JM, van Roij MHH, EltingMW VJI, Wijnaendts LC, Shaw NJ, HoglerW MKC, Sistermans EA, Dalton A, Meijers-Heijboer H, Pals G (2009) PPIB mutations cause severe osteogenesis imperfecta. Am J Hum Genet 85:521\u2013527","journal-title":"Am J Hum Genet"},{"key":"3216_CR7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ajhg.2010.01.034","volume":"86","author":"HE Christiansen","year":"2010","unstructured":"Christiansen HE, Schwarze U, Pyott SM, AlSwaid A, Al Balwi M, Alrasheed S et al (2010) Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet 86:389\u2013398","journal-title":"Am J Hum Genet"},{"key":"3216_CR8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ajhg.2012.06.005","volume":"91","author":"TJ Cho","year":"2012","unstructured":"Cho TJ, Lee KE, Lee SK, Song SJ, Kim KJ, Jeon D, Lee G, Kim HN, Lee HR, Eom HH, Lee ZH, Kim OH, Park WY, Park SS, Ikegawa S, Yoo WJ, Choi IH, Kim JW (2012) A single recurrent mutation in the 5-prime UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet 91:343\u2013348","journal-title":"Am J Hum Genet"},{"key":"3216_CR9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajhg.2010.05.016","volume":"87","author":"P Lapunzina","year":"2010","unstructured":"Lapunzina P, Aglan M, Temtamy S, Caparr\u00f3s-Mart\u00edn JA, Valencia M, Let\u00f3n R, Mart\u00ednez-Glez V, Elhossini R, Amr K, Vilaboa N, Ruiz-Perez VL (2010) Identification of a frameshift mutation in osterix in a patient with recessive osteogenesis imperfecta. Am J Hum Genet 87:110\u2013114","journal-title":"Am J Hum Genet"},{"key":"3216_CR10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/humu.21647","volume":"33","author":"V Mart\u00ednez-Glez","year":"2012","unstructured":"Mart\u00ednez-Glez V, Valencia M, Caparr\u00f3s-Mart\u00edn JA, Aglan M, Temtamy S, Tenorio J, Pulido V, Lindert U, Rohrbach M, Eyre D, Giunta C, Lapunzina P, Ruiz-Perez VL (2012) Identification of a mutation causing deficient BMP1\/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta. Hum Mutat 33:343\u2013350","journal-title":"Hum Mutat"},{"key":"3216_CR11","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/humu.22133","volume":"33","author":"MT Puig-Herv\u00e1s","year":"2012","unstructured":"Puig-Herv\u00e1s MT, Temtamy S, Aglan M, Valencia M, Mart\u00ednez-Glez V, Ballesta-Mart\u00ednez MJ, L\u00f3pez-Gonz\u00e1lez V, Ashour AM, Amr K, Pulido V, Guill\u00e9n-Navarro E, Lapunzina P, Caparr\u00f3s-Mart\u00edn JA, Ruiz-Perez VL (2012) Mutations in PLOD2 cause autosomal recessive connective tissue disorders within the Bruck syndrome-osteogenesis imperfecta phenotypic spectrum. Hum Mutat 33:1444\u20131449","journal-title":"Hum Mutat"},{"key":"3216_CR12","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ajhg.2013.02.009","volume":"92","author":"SM Pyott","year":"2013","unstructured":"Pyott SM, Tran TT, Leistritz DF, Pepn MG, Mendelsohn NJ, Temme RT, Fernandez BA, Elsayed SM, Elsobky E, Verma I, Nair S, Turner EH, Smith JD, Jarvik GP, Byers PH (2013) WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am J Hum Genet 92:590\u2013597","journal-title":"Am J Hum Genet"},{"key":"3216_CR13","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ajmg.a.33909","volume":"155A","author":"ML Warman","year":"2011","unstructured":"Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, LeMerrer M, Mortier G, Mundlos S, Nishimura G, Rimoin DL, Robertson S, Savarirayan R, Sillence D, Spranger J, Unger S, Zabel B, Superti-Furga A (2011) Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet 155A:943\u2013968","journal-title":"Am J Med Genet"},{"key":"3216_CR14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence DO, Senn A, Danks DM (1979) Genetic heterogenicity in osteogenesis imperfecta. J Med Genet 16:101\u2013116","journal-title":"J Med Genet"},{"key":"3216_CR15","unstructured":"OMIM: Online Mendelian Inheritance in Man.(2015) McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD), and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD). Home page at: http:\/\/www.ncbi.nlm.nih.gov\/omim ."},{"key":"3216_CR16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11832-012-0385-3","volume":"6","author":"MS Aglan","year":"2012","unstructured":"Aglan MS, Hosny L, El-Houssini R, Abdelhadi S, Salem F, Awad SA, Zaki ME, ElBanna RAS, Temtamy SA (2012) A scoring system for assessment of severity in osteogenesis imperfecta. J Child Orthop 6:29\u201335","journal-title":"J Child Orthop"},{"key":"3216_CR17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev-genet-110711-155608","volume":"46","author":"PH Byers","year":"2012","unstructured":"Byers PH, Pyott SM (2012) Recessively inherited forms of osteogenesis imperfecta. Annu Rev Genet 46:475\u2013497","journal-title":"Annu Rev Genet"},{"key":"3216_CR18","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1073\/pnas.96.3.1054","volume":"96","author":"RA Bank","year":"1999","unstructured":"Bank RA, Robins SP, Wijmenga C, Breslau-Siderius LJ, Bardoel AF, Van der Sluijs HA et al (1999) Defective collagen crosslinking in bone, but not in ligament or cartilage, in Bruck syndrome: indications for a bone-specific telopeptide lysyl hydroxylase on chromosome 17. Proc Natl Acad Sci 96:1054\u20131058","journal-title":"Proc Natl Acad Sci"},{"key":"3216_CR19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajmg.a.30231","volume":"131","author":"R Ha-Vinh","year":"2004","unstructured":"Ha-Vinh R, Alanay Y, Bank RA et al (2004) Phenotypic and molecular characterization of Bruck syndrome (osteogenesis imperfecta with contractures of the large joints) caused by a recessive mutation in PLOD2. Am J Med Genet A 131:115\u2013120","journal-title":"Am J Med Genet A"},{"key":"3216_CR20","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/jbmr.250","volume":"26","author":"BP Kelley","year":"2011","unstructured":"Kelley BP, Malfait F, Bonafe L, Baldridge D, Homan E et al (2011) Mutations in FKBP10 cause recessive osteogenesis imperfecta and Bruck syndrome. J Bone Miner Res 26:666\u2013672","journal-title":"J Bone Miner Res"},{"key":"3216_CR21","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/ajmg.a.34025","volume":"155","author":"R Shaheen","year":"2011","unstructured":"Shaheen R, Al-Owain M, Faqeih E, Al-Hashmi N, Awaji A, Al-Zayed Z et al (2011) Mutations in FKBP10 cause both Bruck syndrome and isolated osteogenesis imperfecta in humans. Am J Med Genet A 155:1448\u20131452","journal-title":"Am J Med Genet A"},{"key":"3216_CR22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejmg.2011.10.002","volume":"55","author":"ED Setijowati","year":"2012","unstructured":"Setijowati ED, van Dijk FS, Cobben JM, van Rijn RR, Sistermans EA et al (2012) A novel homozygous 5 bp deletion in FKBP10 causes clinically Bruck syndrome in an Indonesian patient. Eur J Med Genet 55:17\u201321","journal-title":"Eur J Med Genet"},{"key":"3216_CR23","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/ajmg.a.35938","volume":"161","author":"JA Caparr\u00f3s-Martin","year":"2013","unstructured":"Caparr\u00f3s-Martin JA, Valencia M, Pulido V, Mart\u00ednez-Glez V, Rueda-Arenas I et al (2013) Clinical and molecular analysis in families with autosomal recessive osteogenesis imperfecta identifies mutations in five genes and suggests genotype-phenotype correlations. Am J Med Genet A 161:1354\u20131369","journal-title":"Am J Med Genet A"},{"key":"3216_CR24","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/B978-0-12-374602-3.00042-0","volume-title":"Osteoporosis in men","author":"JR Shapiro","year":"2010","unstructured":"Shapiro JR (2010) Inherited and related disorders of bone matrix synthesis in men. In: Orwoll E, Bilezikian J, Vanderschueren D (eds) Osteoporosis in men, 2nd edn. Academic, San Diego, pp 505\u2013522","edition":"2"},{"key":"3216_CR25","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947\u2013952","journal-title":"N Engl J Med"},{"key":"3216_CR26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3346\/jkms.2007.22.2.209","volume":"22","author":"JH Choi","year":"2007","unstructured":"Choi JH, Shin YL, Yoo HW (2007) Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta. J Korean Med Sci 22:209\u2013212","journal-title":"J Korean Med Sci"},{"key":"3216_CR27","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1515\/jpem-2012-0016","volume":"25","author":"ER Barros","year":"2012","unstructured":"Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M (2012) Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfect. J Pediatr Endocrinol Metab 25:485\u2013491","journal-title":"J Pediatr Endocrinol Metab"},{"key":"3216_CR28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00223-012-9588-3","volume":"90","author":"T Cundy","year":"2012","unstructured":"Cundy T (2012) Recent advances in osteogenesis imperfecta. Calcif Tissue Int 90:439\u2013449","journal-title":"Calcif Tissue Int"},{"key":"3216_CR29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000323368","volume":"75","author":"I Vuorimies","year":"2011","unstructured":"Vuorimies I, Toiviainen-Salo S, Hero M, Makitie O (2011) Zoledronic acid treatment in children with osteogenesis imperfecta. Horm Res Paediatr 75:346\u2013353","journal-title":"Horm Res Paediatr"},{"key":"3216_CR30","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/jc.2008-1531","volume":"94","author":"LK Bachrach","year":"2009","unstructured":"Bachrach LK, Ward LM (2009) Clinical review 1: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 94:400\u2013409","journal-title":"J Clin Endocrinol Metab"},{"key":"3216_CR31","unstructured":"SPSS 18.0: SPSS Inc. Released (2009). PASW Statistics for Windows, Chicago"},{"key":"3216_CR32","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ajhg.2013.02.010","volume":"92","author":"K Keupp","year":"2013","unstructured":"Keupp K, Beleggia F, Kayserili H, Barnes AM, Steiner M, Semler O, Fischer B, Yigit G, Janda CY, Becker J, Breer S, Altunoglu U, Gr\u00fcnhagen J, Krawitz P, Hecht J, Schinke T, Makareeva E, Lausch E, Cankaya T, Caparr\u00f3s-Mart\u00edn JA, Lapunzina P, Temtamy S, Aglan M, Zabel B, Eysel P, Koerber F, Leikin S, Garcia KC, Netzer C, Sch\u00f6nau E, Ruiz-Perez VL, Mundlos S, Amling M, Kornak U, Marini J, Wollnik B (2013) Mutations in WNT1 cause different forms of bone fragility. Am J Hum Genet 92:565\u2013574","journal-title":"Am J Hum Genet"},{"key":"3216_CR33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00296-010-1586-z","volume":"31","author":"SP Salari","year":"2011","unstructured":"Salari SP, Abdollahi M, Larijani B (2011) Current, new and future treatments of osteoporosis. Rheumatol Int 31:289\u2013300","journal-title":"Rheumatol Int"},{"key":"3216_CR34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11154-008-9074-4","volume":"9","author":"MS Cheung","year":"2008","unstructured":"Cheung MS, Cheung FH (2008) Osteogenesis imperfecta: update on presentation and management. Rev Endocr Metab Disord 9:153\u2013160","journal-title":"Rev Endocr Metab Disord"},{"key":"3216_CR35","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","volume":"363","author":"F Rauch","year":"2004","unstructured":"Rauch F, Glorieux FH (2004) Osteogenesis imperfecta. Lancet 363:1377\u20131385","journal-title":"Lancet"},{"key":"3216_CR36","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/01.bpb.0000192058.98484.5b","volume":"15","author":"MA El-Sobky","year":"2006","unstructured":"El-Sobky MA, Hanna AA, Basha NE, Tarraf YN, Said MH (2006) Surgery versus surgery plus pamidronate in the management of osteogenesis imperfecta patients: a comparative study. J Pediatr Orthop B 15:222\u2013228","journal-title":"J Pediatr Orthop B"},{"key":"3216_CR37","doi-asserted-by":"crossref","unstructured":"Rauch F (2014) Bisphosphonate treatment and related agents in children. In Shapiro JR, Byers PH, Glorieux FH and Sponsellor PD (eds). Osteogenesis imperfecta. San Diego. 501\u2013507","DOI":"10.1016\/B978-0-12-397165-4.00054-X"},{"key":"3216_CR38","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bone.2007.05.002","volume":"41","author":"CF Munns","year":"2007","unstructured":"Munns CF, Rajab MH, Hong J, Briody J, Hogler W, McQuade M, Little DG, Cowell CT (2007) Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone 41:366\u2013370","journal-title":"Bone"},{"key":"3216_CR39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1515\/JPEM.2009.22.1.55","volume":"22","author":"JJ Brown","year":"2009","unstructured":"Brown JJ, Zacharin MR (2009) Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. J Pediatr Endocrinol Metab 22:55\u201363","journal-title":"J Pediatr Endocrinol Metab"},{"key":"3216_CR40","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00774-009-0149-4","volume":"28","author":"I Panigrahi","year":"2010","unstructured":"Panigrahi I, Das RR, Sharda S, Marwaha RK, Khandelwal N (2010) Response to zolendronic acid in children with type III osteogenesis imperfecta. J Bone Miner Res 28:451\u2013455","journal-title":"J Bone Miner Res"},{"key":"3216_CR41","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1651-2227.2007.00390.x","volume":"96","author":"K Lowing","year":"2007","unstructured":"Lowing K, Astrom E, Oscarsson KA, Soderhall S, Eliasson AC (2007) Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta. Acta Paediatr 96:1180\u20131183","journal-title":"Acta Paediatr"},{"key":"3216_CR42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1515\/JPEM.2010.23.1-2.73","volume":"23","author":"S Salehpour","year":"2010","unstructured":"Salehpour S, Tavakkoli S (2010) Cyclic pamidronate therapy in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 23:73\u201380","journal-title":"J Pediatr Endocrinol Metab"},{"key":"3216_CR43","first-page":"77","volume":"12","author":"L Zeitlin","year":"2003","unstructured":"Zeitlin L, Fassier F, Glorieux FH (2003) Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop B 12:77\u201387","journal-title":"J Pediatr Orthop B"},{"key":"3216_CR44","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000323370","volume":"75","author":"TJ Heino","year":"2011","unstructured":"Heino TJ, Astrom E, Laurencikas E, Savendahl L, Soderhall S (2011) Intravenous pamidronate treatment improves growth in prepubertal osteogenesis imperfecta patients. Horm Res Paediatr 75:354\u2013361","journal-title":"Horm Res Paediatr"},{"key":"3216_CR45","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pedneo.2013.12.001","volume":"55","author":"CH Lin","year":"2014","unstructured":"Lin CH, Chien YH, Peng SF, Tsai WY, Tung YC, Lee CT, Chien CC, Hwu WL, Lee NC (2014) Cyclic pamidronate infusion for neonatal-onset osteogenesis imperfecta. Pediatr Neonatol 55:306\u2013311","journal-title":"Pediatr Neonatol"},{"key":"3216_CR46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1542\/peds.2006-2023I","volume":"119","author":"FH Glorieux","year":"2007","unstructured":"Glorieux FH (2007) Experience with bisphosphonates in osteogenesis imperfecta. Pediatrics 119:163\u2013165","journal-title":"Pediatrics"},{"key":"3216_CR47","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.bone.2006.10.010","volume":"40","author":"C Land","year":"2007","unstructured":"Land C, Rauch F, Travers R, Glorieux FH (2007) Osteogenesis imperfect type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone 40:638\u2013644","journal-title":"Bone"},{"key":"3216_CR48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/MOP.0b013e328332c68f","volume":"21","author":"JR Shapiro","year":"2009","unstructured":"Shapiro JR, Sponsellor PD (2009) Osteogenesis imperfect: questions and answers. Curr Opin Pediatr 21:709\u2013716","journal-title":"Curr Opin Pediatr"},{"key":"3216_CR49","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bone.2003.11.019","volume":"34","author":"P Arikoski","year":"2004","unstructured":"Arikoski P, Silverwood B, Tillmann V, Bishop NJ (2004) Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone 34:539\u2013546","journal-title":"Bone"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3216-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-015-3216-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3216-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:15:25Z","timestamp":1558610125000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-015-3216-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,3]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["3216"],"URL":"https:\/\/doi.org\/10.1007\/s00198-015-3216-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,3]]}}}